Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant
Status:
Terminated
Trial end date:
2016-08-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether a dosing regimen of eculizumab in addition to
standard posttransplant care in positive crossmatch deceased donor kidney transplant
recipients will reduce the incidence of acute humoral rejection (AHR).
Patients included in this study will be those who have demonstrable anti-human leukocyte
antigen (HLA) antibody specific for their deceased donor. It is our hypothesis that blockade
of terminal complement activation with eculizumab at the time of transplant in combination
with our current protocols will reduce the incidence of AHR in recipients of deceased donor
kidney transplants who have anti-donor HLA antibody